Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment o…
$112.28+6.91%
报价 2026-11-06
市值
$7.73B
EV
$7.69B
PE (TTM)
–
预期 PE (FY2026)
–
52 周区间距高点 -4.5%
$75.82$117.62
筛选结果
pipeline · 2026-11-06Filter✗ 高增长✗ Cheap✗ GARP
excluded industry: Biotechnology
爆发潜力
2026-11-07不在筛选范围：industry: Biotechnology
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| RYTMRhythm Pharmaceuticals, Inc. | $7.73B | +6.9% | +57.7% | 88.2% | – | – | – | |
| PTGXProtagonist Therapeutics, Inc. | $8.54B | -2.4% | +959.8% | 99.2% | – | – | 147.6x | |
| KNSAKiniksa Pharmaceuticals, Ltd. | $7.37B | +6.2% | – | 54.3% | 64.5x | 49.8x | 36.8x | |
| RLAYRelay Therapeutics, Inc. | $4.08B | +9.4% | -14.8% | 89.7% | – | – | – | |
| VRDNViridian Therapeutics, Inc. | $3.23B | -0.2% | -34.0% | 93% | – | – | – | |
| STOKStoke Therapeutics, Inc. | $1.72B | +1.8% | -86.0% | 98.9% | – | – | 37.8x | |
| QUREuniQure N.V. | $1.51B | +3.3% | – | 22.8% | – | – | – | |
| MGTXMeiraGTx Holdings plc | $864.4M | +5.8% | +105.7% | 91.6% | – | – | – | |
| SNDXSyndax Pharmaceuticals, Inc. | $858.9M | +1.8% | +107.0% | 96% | – | – | – | |
| 同行中位数 | – | – | +45.4% | 92.3% | 64.5x | 49.8x | 37.8x |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
暂无季度数据（首次研究运行后填充）。